Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

被引：0
|
作者：
Arjun Bhadhuri
Daniel Dröschel
Mike Guldimann
Claudia Jetschgo
Judit Banhazi
Matthias Schwenkglenks
C. Simone Sutherland
机构：
[1] Institute of Pharmaceutical Medicine (ECPM),
[2] University of Basel,undefined
[3] Novartis Pharma Schweiz AG,undefined
[4] Novartis Pharma AG,undefined
来源：
BMC Health Services Research | / 22卷
关键词：
RPE65; Cost effectiveness; Health Economics; Inherited retinal disease; Voretigene neparvovec; Switzerland;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland
    Bhadhuri, Arjun
    Droschel, Daniel
    Guldimann, Mike
    Jetschgo, Claudia
    Banhazi, Judit
    Schwenkglenks, Matthias
    Sutherland, C. Simone
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [2] Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy
    Kang, Connie
    Scott, Lesley J.
    MOLECULAR DIAGNOSIS & THERAPY, 2020, 24 (04) : 487 - 495
  • [3] Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy
    Connie Kang
    Lesley J. Scott
    Molecular Diagnosis & Therapy, 2020, 24 : 487 - 495
  • [4] Cost Effectiveness of Voretigene Neparvovec for RPE65-Mediated Inherited Retinal Degeneration in Germany
    Uhrmann, Matthias Fritz
    Lorenz, Birgit
    Gissel, Christian
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2020, 9 (09): : 1 - 8
  • [5] A COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE
    Zimmermann, M. R.
    Lubinga, S. J.
    Rind, D.
    Chapman, R. H.
    Carlson, J. J.
    VALUE IN HEALTH, 2018, 21 : S205 - S206
  • [6] Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease
    Johnson, Scott
    Buessing, Marric
    O'Connell, Thomas
    Pitluck, Sarah
    Ciulla, Thomas A.
    JAMA OPHTHALMOLOGY, 2019, 137 (10) : 1115 - 1123
  • [7] Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease
    Zimmermann, Marita
    Lubinga, Solomon J.
    Banken, Reiner
    Rind, David
    Cramer, Geri
    Synnott, Patricia G.
    Chapman, Richard H.
    Khan, Sonya
    Carlson, Josh
    VALUE IN HEALTH, 2019, 22 (02) : 161 - 167
  • [8] Voretigene neparvovec-rzyl for the treatment of biallelic RPE65 mutation-associated retinal dystrophy
    Russell, Stephen
    Bennett, Jean
    Maguire, Albert M.
    High, Katherine A.
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (08): : 457 - 464
  • [9] COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING
    Ploug, U.
    VALUE IN HEALTH, 2019, 22 : S846 - S846
  • [10] Five-year update for the Phase III voretigene neparvovec study in biallelic RPE65 mutation-associated inherited retinal disease
    Leroy, Bart P.
    Russell, Stephen R.
    Bennett, Jean
    High, Katherine A.
    Drack, Arlene V.
    Yu, Zi-Fan
    Chung, Daniel
    Reape, Kathleen Z.
    Maguire, Albert M.
    Simunovic, Matthew
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 49 (08): : 966 - 967
12345